The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature
Rituximab (RTX), a chimeric monoclonal antibody targeted against CD20, has been used to treat refractory inflammatory myopathies (IIM). The primary objective of this study was to retrospectively assess the efficacy of RTX in reducing disease activity in patients with IIM refractory to conventional t...
में बचाया:
| मुख्य लेखकों: | , , , , , , |
|---|---|
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
PAGEPress Publications
2018-07-01
|
| श्रृंखला: | Reumatismo |
| विषय: | |
| ऑनलाइन पहुंच: | https://www.reumatismo.org/index.php/reuma/article/view/1011 |
| टैग: |
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|